A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation (CARDIOVERT)
A Placebo-controlled, Parallel-group, Double Blind, Randomized, Multi-cohort Phase 2 Study to Investigate Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BAY 3670549 in Adult Participants With Atrial Fibrillation.
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion.
Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body.
The total duration of the study for an individual participant may be up two months.
The findings from this study may contribute to the development of a new treatment option for people with AF.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Bayer Clinical Trials Contact
- Numéro de téléphone: 18888422937
- E-mail: clinical-trials-contact@bayer.com
Lieux d'étude
-
-
Lower Saxony
-
Hanover, Lower Saxony, Allemagne, 30625
- Pas encore de recrutement
- Medizinische Hochschule Hannover|Kardiologie und Angiologie
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, Allemagne, 32545
- Pas encore de recrutement
- Herz-und Diabeteszentrum NRW|Elektrophysiologie/Rhythmologie
-
-
Thuringia
-
Altenburg, Thuringia, Allemagne, 04600
- Recrutement
- Klinikum Altenburger Land GmbH-Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin
-
-
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgique, 3000
- Recrutement
- UZ Leuven Gasthuisberg - Cardiology diseases department
-
-
Limburg
-
Hasselt, Limburg, Belgique, 3500
- Pas encore de recrutement
- Jessa Ziekenhuis | Hartcentrum Hasselt
-
-
West Flanders
-
Roeselare, West Flanders, Belgique, 8800
- Pas encore de recrutement
- AZ Delta | Clinical Trial Center - Cardiology
-
-
-
-
Plovdiv Province
-
Plovdiv, Plovdiv Province, Bulgarie, 4001
- Pas encore de recrutement
- University Multiprofile Hospital For Active Treatment Sveti Georgi' - EAD Department of Intensive Cardiology"
-
-
Sofia City Province
-
Sofia, Sofia City Province, Bulgarie, 1233
- Pas encore de recrutement
- Multiprofile Hospital for Active Treatment Knyaginya Klementina Sofia EAD | Cardiology Department
-
Sofia, Sofia City Province, Bulgarie, 1527
- Recrutement
- University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Cardiology Clinic
-
-
Veliko Tarnovo Province
-
Veliko Tarnovo, Veliko Tarnovo Province, Bulgarie, 5000
- Recrutement
- Multiprofile Hospital for Active Treatment Dr. Stefan Cherkezov | Base 1 - Cardiology Department
-
-
-
-
-
Budapest, Hongrie, 1122
- Recrutement
- Semmelweis Egyetem, Varosmajori Sziv- és Ergyogyaszati Klinika
-
-
Tolna County
-
Szekszárd, Tolna County, Hongrie, 7100
- Pas encore de recrutement
- Tolna Vármegyei Balassa János Kórház - I. Belgyógyászati Osztály: Kardiológia, Nefrológia
-
-
-
-
Apulia
-
Acquaviva delle Fonti, Apulia, Italie, 70021
- Recrutement
- Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC
-
-
Lazio
-
Rome, Lazio, Italie, 00161
- Pas encore de recrutement
- Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari
-
-
Lombardy
-
Milan, Lombardy, Italie, 20138
- Recrutement
- Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica
-
-
The Marches
-
Torrette, The Marches, Italie, 60126
- Pas encore de recrutement
- Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia
-
-
-
-
-
Groningen, Pays-Bas, 9713 GZ
- Pas encore de recrutement
- Universitair Medisch Centrum Groningen
-
-
Limburg
-
Maastricht, Limburg, Pays-Bas, 6229 HX
- Pas encore de recrutement
- Maastricht UMC
-
-
-
-
Lesser Poland Voivodeship
-
Chrzanów, Lesser Poland Voivodeship, Pologne, 32-500
- Pas encore de recrutement
- American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Pologne, 20-090
- Pas encore de recrutement
- USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio.
-
-
Masovian Voivodeship
-
Grodzisk Mazowiecki, Masovian Voivodeship, Pologne, 05-825
- Recrutement
- Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II
-
-
Silesian Voivodeship
-
Bielsko-Biala, Silesian Voivodeship, Pologne, 43-316
- Pas encore de recrutement
- American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii
-
-
-
-
California
-
San Francisco, California, États-Unis, 94143
- Retiré
- UCSF Advanced Heart Failure Comprehensive Care Center
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Pas encore de recrutement
- UCHealth University of Colorado Hospital - Cardiology
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Pas encore de recrutement
- Massachusetts General Hospital - Cardiology
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Hospital - Cardiology
-
-
Minnesota
-
Maplewood, Minnesota, États-Unis, 55109
- Retiré
- M Health Fairview Heart Clinic - Maplewood
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27704
- Pas encore de recrutement
- Duke University Hospital - Cardiology
-
-
Texas
-
Fort Worth, Texas, États-Unis, 76104
- Pas encore de recrutement
- Texas Health Heart and Vascular Specialists - Fort Worth
-
Tyler, Texas, États-Unis, 75701
- Pas encore de recrutement
- CHRISTUS Trinity | Mother Frances Louis and Peaches Owen Heart Hospital - Electrophysiology Clinic
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent.
- Participant is hemodynamically stable and does not require emergency cardioversion, as determined by the investigator.
- Participant has a current episode of atrial fibrillation (AF) ongoing for at least 3 hours and no more than 30 days at the time of randomization.
- Participant has an indication for electrical cardioversion of AF, as determined by the investigator according to standard clinical practice and national/institutional guidelines.
- At randomization, successful initiation and achievement of therapeutic levels of anticoagulation therapy, as well as completion of imaging evaluation for left atrial thrombi, as appropriate for the duration of the AF episode and risk for the participant according to national guideline and institution-specific routine practice.
- BMI within range [18 - 39.9] kg/m2.
- Contraceptive use by participants or participant partners should be consistent with the study protocol and local regulations regarding the methods of contraception for those participating in clinical studies.
- Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Willing and able to comply with the receipt, home use, and return of the continuous ECG recording device, as well as with the participation in scheduled telephone follow-up assessments.
Exclusion Criteria:
-
Current atrial flutter (AFL) or combined AF/AFL
-
Contraindication for electrical cardioversion on planned treatment day
-
Documented severely dilated left atrium (left atrial diameter, LAD >5 cm) measured by any modality within the 6 months prior to screening; if several values are available, the most recent one shall be reported. If left atrium diameter was not measured in the last 6 months or a major cardiovascular event occurred within the last 6 months, a new measurement must be done at screening
-
Unsuccessful conversion of current AF episode (pharmacologically or electrically)
-
Known severe valvular heart disease (e.g., severe mitral regurgitation, severe aortic stenosis)
-
Patients with NYHA Class ≥ III heart failure, or with active management of acute heart failure decompensation on treatment day.
-
History within the preceding 3 months prior to randomization of any of the following events, or any other significant cardiovascular event as judged by the investigator:
- Stroke
- Myocardial infarction
- Unstable angina pectoris or other signs of myocardial ischemia
- Cardiac surgery
- Transcatheter valve replacement
- Percutaneous coronary intervention (PCI)
- Coronary artery bypass graft (CABG) or other revascularization procedure
-
Severe renal impairment, i.e., estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² (using CKD-EPI formula) or requiring dialysis
-
Severe hepatic impairment, i.e. Child Pugh Class C
-
Use of anti-arrhythmic class I or III drugs within 5 half-lives before study drug administration (oral amiodarone in the previous 3 months)
-
Hypertension with SBP ≥ 180 mmHg or hypotension (SBP < 90 mmHg) at randomization (based on the second BP measurement)
-
Stressor-associated AF, i.e., in the setting of an acute and reversible stressor (e.g., cardiac surgery, myocarditis, endocarditis, sepsis, pneumonia, etc.). This includes ablation procedure within the preceding one month prior to randomization.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
intravenous (IV) treatment |
|
Expérimental: BAY 3670549
|
intravenous (IV) treatment |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion
Délai: Up to 3 hours after start of administration of study intervention
|
AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care; |
Up to 3 hours after start of administration of study intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants who experienced Treatment Emergent Adverse Events (TEAE)s
Délai: From pre-dose* up to 48 hours after start of administration of study intervention
|
TEAE = Treatment Emergent Adverse Events; *Pre-dose: Within 4 hours prior to study intervention administration |
From pre-dose* up to 48 hours after start of administration of study intervention
|
|
Time to conversion from AF to SR as defined in the primary endpoint
Délai: Up to 3 hours after start of administration of study intervention
|
AF = atrial fibrillation SR = sinus rhythm; |
Up to 3 hours after start of administration of study intervention
|
|
Number of Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion
Délai: Up to 3 hours after start of administration of study intervention
|
SoC = Standard of Care; |
Up to 3 hours after start of administration of study intervention
|
|
Plasma concentration of BAY 3670549 at the end of the infusion
Délai: From pre-dose* up to 8 hours after start of administration of study intervention
|
*Pre-dose: Within 4 hours prior to study intervention administration |
From pre-dose* up to 8 hours after start of administration of study intervention
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 22961
- 2025-523807-31-00 (Ctis)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .